SHINE and IOCB Prague deliver Lu-177 dose to GE Healthcare, advance therapeutic isotope
January 22, 2020
SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient dose quantities of the therapeutic isotope lutetium-177 (Lu-177). The lot passed GE Healthcare’s quality control testing, including internationally recognized radionuclide purity (RNP) standards. The delivery of Lu-177 in this quantity and purity demonstrates the suitability of the IOCB technology for Lu-177 production. It is a major step toward commercial production of the therapeutic isotope by SHINE.
“Lu-177 is one of the key drivers of growth in the medical isotope market. It represents a major opportunity to better serve the market,” said Charles Shanks, GE Healthcare’s principal engineer, Life Sciences.